Global

Aug 10, 2016
If managed access is to be a widely available option, it makes sense to re-assess just how much should be spent on it, writes Leela Barham.
Jul 29, 2016
A ‘new’ version of the English Cancer Drugs Fund (CDF) comes into force today. Leela Barham reports.
Jul 29, 2016
Paul Ranson examines how the UK biopharma must now adapt to a changing landscape.
Jul 27, 2016
Leela Barham looks at the EU plans for a European patent, and asks where the UK will fit in after Brexit.
Jul 20, 2016
Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach.
Jul 12, 2016
Pharmaceutical Executive
A look at how Europe’s new accelerated drug approval scheme can move existing review pathways to something better—and take a page from the FDA experience as well.
Jul 07, 2016
The long planned for transparency of industry payments to doctors, pharmacists, nurses and others has shone some dappled light on the UK industry, writes Leela Barham.
Jul 05, 2016
The UK's Brexit vote has unleashed turbulence in Europe — not least on its pharma sector. Reflector reports.
Jul 01, 2016
Leela Barham looks at the implications for the UK industry in the aftermath of last week's vote for Brexit.
Jun 09, 2016
Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision.
native1_300x100
lorem ipsum